An international expert panel (EBMT, ISCT, JACIE) updated their 2024 consensus recommendations on CAR T-cell therapy for severe, refractory autoimmune diseases — including rheumatic, neurological, haematological, and paediatric indications — covering patient selection, clinical management, follow-up, and immune monitoring.
The 2026 update provides expert-based, disease-specific guidance across multiple autoimmune conditions, reflecting accumulated evidence since CAR T cells first emerged as a treatment option for autoimmune diseases in 2021; specific outcome data beyond expert consensus are not reported in the abstract.
Recommendations are expert consensus-based rather than derived from randomised controlled trials, limiting the strength of the evidence; the target diseases are heterogeneous, making uniform guidance difficult; and as 'living recommendations,' they may not yet reflect the most recently published trial data.
Clinicians managing patients with severe, refractory autoimmune diseases should consult these updated EBMT–ISCT–JACIE recommendations for disease-specific guidance on when and how to use CAR T-cell therapy, including patient selection criteria and monitoring protocols.